Home

23andMe Holding Co. - Common Stock (ME)

0.7700
+0.2395 (45.15%)

23andMe Holding Co. is a biotechnology company that specializes in personal genomics and biotechnology research

It offers direct-to-consumer genetic testing services, allowing individuals to explore their ancestry, health risks, and genetic traits through easy-to-use saliva collection kits. The company aims to empower people with insights into their genetic information and provide valuable resources for health-related decision-making. Additionally, 23andMe is involved in pharmaceutical research, leveraging its vast genetic database to facilitate drug discovery and development through collaborations with various biopharmaceutical companies.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close0.5305
Open0.6025
Bid0.7108
Ask0.7363
Day's Range0.5936 - 1.370
52 Week Range0.5300 - 12.76
Volume179,451,497
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume8,755,639

News & Press Releases

Top movers in Thursday's sessionchartmill.com
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 27, 2025
These stocks are the most active in today's sessionchartmill.com
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · March 27, 2025
Top stock movements in today's session.chartmill.com
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 27, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · March 27, 2025
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
Receives Court Approval for First Day Motions to Support Ongoing Business Operations
By 23andMe, Inc. · Via GlobeNewswire · March 26, 2025
Cybersecurity Stocks To Outperform, It's The 'One Line Item That No Company In The World Is Cutting': Josh Brownbenzinga.com
Cybersecurity is "the one line item that no company in the world is cutting," Brown said, noting how a data breach brought down 23andMe.
Via Benzinga · March 26, 2025
23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customersbenzinga.com
23andMe files for Chapter 11 bankruptcy, raising concerns about genetic data security as legal challenges emerge over a $30 million data breach settlement.
Via Benzinga · March 25, 2025
US Stocks Likely To Open Lower After 2-Day Advance: Clear And Measured Tariff Plan Could 'Trigger A Strong Relief Rally,' Says Expertbenzinga.com
U.S. stock futures declined on Tuesday, after advancing for two consecutive sessions on Friday and Monday.
Via Benzinga · March 25, 2025
Microalgo, Palantir, 23Andme, AMD, And Tesla: Why These 5 Stocks Are On Investors' Radars Todaybenzinga.com
The S&P 500 and Nasdaq posted their best gains in months, with the S&P 500 climbing 1.76% to 5,767.57 and the Nasdaq rising 2.3% to 18,188.59.
Via Benzinga · March 24, 2025
What's going on in today's sessionchartmill.com
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · March 24, 2025
These stocks are moving in today's sessionchartmill.com
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · March 24, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · March 24, 2025
Traders are paying attention to the gapping stocks in Monday's session.chartmill.com
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · March 24, 2025
Crude Oil Gains 1%; US Composite PMI Surges In Marchbenzinga.com
Via Benzinga · March 24, 2025
Discover the top movers in Monday's pre-market session.chartmill.com
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 24, 2025
Dow Jumps Over 300 Points; Chicago Fed National Activity Index Rises In Februarybenzinga.com
Via Benzinga · March 24, 2025
Why Is DNA Test Provider 23andMe Stock Tumbling Today?benzinga.com
Shares of 23andMe are falling in premarket trading after the company filed for Chapter 11 bankruptcy to initiate a court-supervised sale process aimed at maximizing business value.
Via Benzinga · March 24, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 24, 2025
US Stocks Likely To Open Higher As Trump May Soften Tariff Plans: Analysts Brush Off Bear Hug Fearsbenzinga.com
Stock futures rise on bullish sentiment as Trump administration plans targeted tariffs against trading partners.
Via Benzinga · March 24, 2025
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 24, 2025
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities
By 23andMe, Inc. · Via GlobeNewswire · March 23, 2025
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels
By 23andMe, Inc. · Via GlobeNewswire · March 21, 2025
Monday's pre-market session: top gainers and loserschartmill.com
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 3, 2025
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki’s proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchange Commission earlier today, represented an 84% decrease to the $2.53 per share price included in the joint non-binding proposal previously submitted by Ms. Wojcicki and her then co-bidder on February 20, 2025.
By 23andMe, Inc. · Via GlobeNewswire · March 3, 2025
Trump's Metal Tariffs Set Stage For US Steel ETF Gainsbenzinga.com
Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.
Via Benzinga · February 12, 2025